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One of the mechanisms through which advanced prostate cancer (PCa) usually relapses after androgen 
deprivation therapy (ADT) is the adaptation to residual androgens in PCa tissue. It has been observed that 
androgen biosynthesis in PCa tissue plays an important role in this adaptation. In the present study, we 
investigated how stromal cells affect adrenal androgen DHEA metabolism in androgen-sensitive PCa 
LNCaP cells. DHEA alone had little effect on PSA promoter activity and the proliferation of LNCaP cells.  
However, the addition of prostate stromal cells (PrSC) or PCa-derived stromal cells (PCaSC) increased 
DHEA-induced PSA promoter activity via androgen receptor activation in the LNCaP cells. Moreover, 
PCaSC stimulated the proliferation of LNCaP cells under physiological concentrations of DHEA. 
Biosynthesis of testosterone or DHT from DHEA in stromal cells and LNCaP cells was involved in this 
stimulation of LNCaP cell proliferation. Androgen biosynthesis from DHEA depended upon the activity 
of various steroidogenic enzymes present in stromal cells. Finally, the dual 5α-reductase inhibitor 
dutasteride appears to function not only as 5α-reductase inhibitor but also as 3β-hydroxysteroid 
dehydrogenase inhibitor in LNCaP cells. Taken together, this coculture assay system provides new 
insights of coordinate androgen biosynthesis under the microenvironment of PCa cells before and after 
ADT, and offers a model system for the identification of important steroidogenic enzymes involved in 
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PCa progression and for the development of the corresponding inhibitors of androgen biosynthesis. 
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Prostate cancer (PCa) is the most common malignancy and the second leading cause of 
cancer-related death of men in the United States (1). Since advanced PCa is initially dependent upon 
androgens, androgen-deprivation therapy (ADT) is the first choice for advanced PCa. Unfortunately, after 
an initial response to ADT, PCa eventually loses responsiveness to the androgen blockade and progresses 
into what is termed an androgen non-responsive phenotype. 
Multiple molecular mechanisms that could account for the development of resistance to ADT have 
been proposed (2) that typically invoke the androgen receptor (AR) as a key mediator in the progression of 
PCa (3,4). Moreover, alterations of AR itself, which are either absent or at low frequency in the original 
androgen-dependent state, result in an androgen-hypersensitive situation where stimulation of PCa 
growth occurs at castrate levels of androgens (4). One of the AR alterations that occurs is AR mutation 
that results in promiscuous ligand specificity (5). Therefore, in addition to its normal ligands, testosterone 
(T) and dihydrotestosterone (DHT), both androstenediol, a precursor of T, and estradiol can activate the 
AR and stimulate the proliferation of LNCaP cells which have a mutated AR (6,7). T and the more active 
androgen DHT are important factors in PCa progression.  These hormone are still present in PCa tissue 
after ADT. Specifically, when PCa patients are treated with ADT, serum T and DHT decreases to less than 
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one-tenth of pretreatment levels (8). However, T and DHT in PCa tissue are still present at 20 to 40% of 
pretreatment values (7-12). These remaining androgens that are still present post-therapy may continue to 
promote AR activation and account for the observation that combination therapy with a LH-RH agonist, 
to block androgen production, and an antiandrogen, to block ligand binding to the AR, is more effective 
for PCa treatment than either therapy alone (8,13,14). 
T and DHT in PCa tissue after medical or surgical castration are synthesized locally in the prostate 
from dehydroepiandrosterone (DHEA) of adrenal origin (7-12). The metabolism from DHEA to DHT in 
peripheral target tissues depends upon the level of expression of various steroidogenic enzymes in the 
specific cell types of these tissues (15). Adrenal DHEA is converted to T by 17β-hydroxysteroid 
dehydrogenase (17β-HSD) and 3β-HSD. T is then converted to DHT by 5α-steroid reductase (SRD5A) in 
the prostate (15-18). Currently, two types of 3β-HSD, fifteen types of 17β-HSDs and 3 types of SRD5A 
have been identified and localized in various peripheral tissues, including the prostate, with specific 
expression patterns in each tissue (18,19). For example, 3β-HSD and type 5 17β-HSD were localized in 
basal cells of alveoli, stromal cells and endothelial cells of blood vessels of the prostate (20). Fung et al. 
have observed increased expression of AKR1C3 (type 5 17β-HSD) in PCa tissue (21) while Stanbrough et 
al. confirmed that ADT-resistant PCa and bone marrow metastases expressed increased levels of multiple 
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genes responsible for androgen metabolism (HSD3B2, AKR1C3, SRD5A1, AKR1C2, AKR1C1 and 
UGT2B15) (22). These studies provide support for the concept that PCa tissues can perform local 
biosynthesis of T and DHT resulting in activation of the AR (23). 
It remains unclear; however, in which cell types T and DHT are converted from DHEA to other 
androgens in PCa tissue, although the products from DHEA and the relevant steroidogenic enzymes are 
definitively present in the prostate. In this study, we explored the hypothesis that PCa stromal cells 
contribute to the biosynthesis of T and DHT in PCa. We demonstrated that T and DHT synthesized from 
DHEA in stromal cells activated AR in PCa epithelial cells in a paracrine fashion and thus contribute to 
the development of ADT resistance in PCa. 
 
Materials and Methods 
Isolation of Stromal Cells from Prostate Carcinoma Tissue. All studies were approved by the 
Institutional Review Board.  We obtained informed consent for experimental use of all specimens 
obtained from prostate needle biopsy or surgical procedure. The characteristics of PCa patients is 
described in Table 1. Stromal cells were isolated using a modification of a previously described method 
(24). Briefly, small pieces of PCa tissue were minced with scissors and washed twice with 
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phosphate-buffered saline. The fragments were then digested in 0.25% trypsin-EDTA (Invitrogen, 
Carlsbad, CA) for 30 min at 37°C. After digestion, the dispersed stromal cells were cultured in RPMI 
supplemented with 1% penicillin/streptomycin and 10% FCS (Sigma, St. Louis, MO) (RPMI-10% FCS) 
on 6 cm dishes. Bone-derived stromal cells 1 (BDSC-1) were obtained from the 11th rib of a 48-year-old 
man during left adrenalectomy for pheochromocytoma. Bone-derived stromal cells 2 (BDSC-2) were 
obtained from the 11th rib of a 58-year-old man during left nephroureterectomy for localized ureteral 
cancer. These bone samples were cut into bone chips and further processed with a bone grinder (25). Bone 
chips were then cultured in RPMI-10% FCS like prostate-derived stromal cells. 
 
Cell Culture and Cell Proliferation Assay.  LNCaP cells were cultured in Dulbecco's modified Eagle 
medium including phenol red-5% FCS (DMEM-5% FCS). Normal prostate-derived stromal cells, PrSC, 
commercially available (Cambrex, East Rutherford, NJ) were cultured using SCGM BulletKit (Cambrex). 
Twenty-four h after 3 x 104 LNCaP cells were seeded on 12-well plates, aliquots of 3×104 stromal cells 
were plated onto Cell Culture Inserts (1.0 µm pore size 12-well format; Becton Dickinson, Franklin Lakes, 
NJ) with DMEM including phenol red-5% charcoal-stripped FCS (CCS; Hyclone, Logan, UT) in 12-well 
plates for 24 h. Cells were then treated with DHEA, (Sigma, St. Louis, MO), and cultured for 4 days. As a 
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positive control, LNCaP cells were treated with 0.1 nM DHT for 4 days for 24 h without stromal cells. 
Medium and reagents were replaced every 2 days. At the end of the culture period, cells were trypsinized 
and counted in triplicate using a hemocytometer. All coculture studies were performed in DMEM-5% 
CCS. These experiments were performed at least twice to obtain reproducible data. 
 
Coculture, Transfection, and Luciferase Assay. To evaluate AR transcriptional activity, 24 h after 
plating 5 x 104 cells on 12-well plates in DMEM including phenol red-5% CCS, LNCaP cells were 
transfected using Lipofectamine transfection reaction (Invitrogen, Carlsbad, CA) using 0.4 µg of 
luciferase reporter plasmid, pGLPSAp-5.8, driven by a 5.8 kb PSA promoter including 
androgen-response elements (26). Twelve h after transfection, LNCaP cells were cocultured with 5 x 104 
srtomal cells for 12 h, followed by the addition of indicated concentration of DHEA for 24 h. Cells were 
then harvested 24 h after addition of reagents and lysed in luciferase lysis buffer (Promega WI). As a 
positive control, transfected LNCaP cells were treated with 0.1 nM DHT for 24 h without stromal cells. To 
block AR and SRD5A activity, we used 1 µM bicalutamide and 5 µM dutasteride (Nacalai tesque Kyoto, 
Japan). To knockdown AR expression in LNCaP cells by RNA interference, 5 x 104 LNCaP cells were 
transfected with 20 nM Non-target (NT) siRNA, AR siRNA-1, or AR siRNA-2 (Invitrogen) using 
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RNAiMAX (Invitrogen) for 12h, LNCaP cells were transfected with pGL3PSAp-5.8 for 12 h. Then after 
changing medium, transfected LNCaP cells were cocultured with or without PrSC. Consequently, cells 
were treated with or without 100 nM DHEA (+) for 24 h. As a positive control, cells were treated with 0.1 
nM DHT for 24 h. For knockdown of AR expression in PrSC by RNA interference, we transfected 3 x 105 
PrSC on a 6 cm dish with 50 nM Stealth RNAi Negative Control Duplex or AR Stealth RNAi 
(5’-CAUAGUGACACCCAGAAGCUUCAUC-3’) (Invitrogen) for 48 h with Lipofectamine RNAiMAX. 
Transfected cells were counted and 5 x 104 siRNA-transfected PrSC were cocultured with 5 x 104 LNCaP 
cells transfected with pGL3PSAp-5.8 12 h before coculture. Total RNA was extracted from the aliquot of 
PrSC transfected with AR siRNA. Knockdown of AR expression was confirmed by RT-PCR analysis. 
These experiments were performed at least twice to provide reproducible data. 
 
Quantitative Analysis of androgens in the medium by LC-ESI-MS/MS. Before harvesting cells, we 
collected the cultured medium and froze it at -30°C until LC-ESI-MS/MS was performed as described 
previously (7). For LC-ESI-MS/MS, 0.5 ml of the cultured medium was diluted with 0.5 ml of distilled 
water and then was 5 ng of androstenediol-2H4 (A-d4), 5 ng [16,16,17-2H3]-T (100 pg), 
[17,16,16-2H3]-DHT (100 pg), [2,2,4α,6-2H4]-DHEA (200 pg), [2,2,4,6,6,16,16-2H7]- androstenedione 
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(100 pg), and [2,2,4,6-2H4]-Adiol (100 pg) as internal standards were added to the individual samples. 
LC-ESI-MS/MS was performed using an API-4000 triple stage quadrupole mass spectrometer equipped 
with an ESI ion source (Applied Biosystems, Foster City, CA) and an Agilent 1100 HPLC system (Agilent 
Technologies, Santa Clara, CA) with HTC PAL auto-sampler (CTC Analytical, Zwingen, Switzerland). 
The assay was validated to ensure that the result was within the 20% range of accuracy and precision. We 
confirmed that endogenous DHEA, Adiol, Adione, T, and DHT in DMEM-5% CCS were below 
detectable methods. 
 
RNA Extraction and RT-PCR.  Twenty-four h after plating 5 x 104 LNCaP cells or stromal cells were 
treated with or without 10-8 M DHT for 24 h at which time total RNA was purified with RNeasy mini kit 
(QIAGEN, Maryland, USA).  Complementary DNA (cDNA) was made by reverse-transcription (RT) of 
200 ng each total RNA using ThermoScript RT-PCR system (Invitrogen).  Each cDNA sample was 
amplified with ExTaq (TAKARA, Japan).  The sense and antisense primers used and RT-PCR conditions 
are shown in Table 2.  The amplified PCR products were visualized using electrophoresis on a 1.5% 
agarose gel. For quantification of mRNA expression, real-time PCR was performed according to the 
manufacturer’s instructions and using the LightCycler TaqMan Master Solution, PCR primers and 
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Universal probe (Roche Applied Science, Switzerland). The gene expression in each sample was 
quantified as the yield of the target gene relative to that of the glyceraldehyde- 3-phosphate 
dehydrogenase (GAPDH) gene. 
 
Statistical analysis. Student’s t-test, for bivariate comparisons, or ANOVA with Fischer’s least significant 
difference post-hoc test, for multivariate comparisons, were used to determine the statistical significance 




Effect of DHT and DHEA on LNCaP cells in the presence of stromal cells 
In order to investigate AR activity, we transfected LNCaP cells with a luciferase expression 
plasmid driven by the prostate specific antigen (PSA) promoter, pGL3PSAp-5.8, and performed 
luciferase assay because this method is simple, effective, and highly sensitive compared to ELISA for PSA 
protein and quantification of mRNA by RT-PCR (7). When LNCaP cells transfected with pGL3PSAp-5.8 
were treated with DHEA, PSA promoter activity was induced in a dose-dependent manner as previously 
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described (Fig. 1A) (7). However, high concentrations of DHEA were needed to induce PSA promoter 
activity. On the other hand, coculture of LNCaP cells with normal prostate-derived PrSC increased 
DHEA-induced PSA promoter activity in direct relation to the number of added PrSC (Fig. 1A). At the 
addition of 40,000 PrSC increased 100 nM DHEA-induced PSA promoter activity three-fold. 
To study the effect of DHEA and of PrSC on LNCaP proliferation, LNCaP cells were cocultured 
with PrSC in chambers separated by a membrane and treated with DHEA for 4 days (Fig. 1B).  LNCaP 
cell proliferation in the absence of PrSC peaked at 0.1 nM DHT as previously described (7). LNCaP cell 
proliferation in the absence of PrSC was stimulated by DHEA in a dose-dependent manner, as previously 
described (7).  LNCaP cell proliferation was stimulated by coculture with PrSC in the absence of DHEA, 
which suggested that some factors secreted from PrSC stimulated the proliferation of LNCaP cells. The 
addition of 10-30 nM DHEA to the coculture of LNCaP cells and PrSC induced greater proliferation of 
LNCaP cells compared to the addition of PrSC alone. The induction of proliferation produced by DHEA 
was the same that could be attained by 0.1 nM DHT, which stimulates maximal proliferation as previously 
described (7). At 100 nM DHEA, the LNCaP cell proliferation began to decrease.  This finding reflects the 
previously reported observation that DHT induces a biphasic response on LNCaP cell growth (7). 
To determine if the effect of DHEA on PSA promoter activity in the presence of PrSC is 
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mediated through the AR present in LNCaP cells, PrSC, or both we first used the antiandrogen 
bicalutamide to block AR. Bicalutamide (1 µM) blocked DHEA-induced PSA promoter activity in the 
LNCaP and PrSC co-culture indicating that the DHEA-induced PSA promoter activity required the AR 
(Fig. 1C).  However, this experiment does not indicate if the impact on LNCaP AR or PrSC AR or both is 
what mediates the effect. Accordingly, we next blocked AR expression in LNCaP cells to determine if the 
LNCaP AR was required for DHEA-mediated induction of the PSA promoter. We cotransfected LNCaP 
cells with AR siRNA expression plasmids and pGLPSAp-5.8 and treated cells with DHEA in the absence 
and presence of PrSC.   Transfection of LNCaP cells with AR siRNA resulted in greater than 90% 
decrease of AR expression (Fig. 1D).   Knockdown of AR expression in LNCaP cells diminished 
DHEA-induced PSA promoter activation in both the absence and presence of PrSC (Fig. 1D). This 
observation suggests that LNCaP AR expression is required for DHEA-mediated PSA activation both in 
LNCaP cells alone and the increase of DHEA-mediated activation of the PSA promoter in the presence of  
PrSC (as observed in Fig. 1A). To determine if DHEA also mediates its effects on LNCaP cells through a 
requirement for AR in the PrSC, we knocked-down AR expression in PrSC using AR siRNA which 
resulted in decreasing AR expression >90% (Fig. 1E).  Coculture of PrSC transfected with AR shRNA and 
LNCaP had no impact on DHEA-induced PSA promoter compared to coculture of PrSC transfected with 
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non-targeting control shRNA.  These results indicate that DHEA action was increased in the presence of 
PrSC by a mechanism other than via AR in PrSC cells, such as paracrine factors produced in PrSC from 
DHEA metabolites. (Fig. 1E right). 
 
Effect of PCa-derived stromal cells on LNCaP cells 
 To further investigate if the ability of PrSC to promote androgen activity in the LNCaP cells was 
prostate-specific, we examined stromal cells from different tissues. Coculture of LNCaP cells with human 
bone-marrow derived stromal cells (HMSC) and lung-derived stromal cells (HLFa) enhanced 
DHEA-induced PSA promoter activity, although these effects were somewhat lower than with PrSC (Fig. 
2A). 
We next investigated if PCa-derived stromal cells (PCaSC) could regulate DHEA stimulatory 
effects on PSA promoter in LNCaP cells. We performed primary cultures of several PCaSCs from PCa 
tissue obtained by prostate needle biopsy for diagnosis (pathology and stage of patients are described in 
Table 1). All PCaSCs expressed vimentin and keratinocyte growth factor (KGF), thus confirming their 
stromal origin (Fig. 2B). All of PCaSCs increased DHEA-induced PSA promoter activity. PCaSC-1, 2, 5, 
8 and 9 stimulated greater DHEA-induced PSA promoter activity than the PrSC (Fig. 3C). Since PCa 
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often metastasizes to bones, we also cocultured LNCaP cells with bone-derived stromal cells (BDSC-1 
and -2). To confirm that bone origin of the BDSC, we examine for expression of osteoblast factors.  
RT-PCR confirmed that core binding factor α1 (cbfa1), osteopontin (OPN), and osteocalcin (OCN) were 
expressed in both BDSC-1 and 2 indicating that they were of bone origin (Fig. 2B). Both BDSCs 
increased PSA promoter activity induced by DHEA at a level 5.4-7.6-fold higher than observed with PrSC 
(Fig. 2C). 
We next investigated in further detail how coculture with PCaSCs affected the proliferation of 
LNCaP cells in the presence of DHEA. When LNCaP cells were cultured without stromal cells, more than 
10 nM DHEA was necessary to stimulate cell proliferation (Fig. 1B). Furthermore, when LNCaP cells 
were cocultured with PCaSC-5, 8, or 9 in the absence of DHEA, the proliferation of LNCaP cells was 
barely stimulated (compare Fig. 1B with Fig. 2D). In contrast, the addition of DHEA to the coculture of 
PCaSC-5, 8, or 9 with LNCaP cells stimulated LNCaP cell proliferation similar to the induction of the 
PSA promoter activity as described in Fig. 2C (Fig. 2D). This effect was seen even at low DHEA 
concentration (1 nM) in the LNCaP cells cocultured with PCaSC-8 and 9. 
 
Androgen concentration in medium after coculture with stromal cells 
Page 16 of 54
erc@endocrinology.org
Manuscript submitted for review to Endocrine-Related Cancer
For Review Only
 17 
We hypothesized that the change of AR activity in the LNCaP cells induced by stromal cells in 
the presence of DHT and DHEA was influenced by the change of metabolism of androgens caused by 
stromal cells. To test this hypothesis, we examined the change in the concentrations of various androgens 
in the culture medium following coculture with stromal cells. After transfection with pGLPSAp-5.8, 
LNCaP cells cocultured with PrSC or PCaSC-8 were treated with 100 nM DHEA. When LNCaP cells 
were cocultured with PrSC or PCaSC-8 in the presence of DHEA, PSA promoter activity was activated 
2.5 and 8.0 times more than when LNCaP cells were cultured alone, respectively (Fig. 3A).  
In the absence of DHEA, we could not detect T and DHT in LNCaP and stromal cells using 
LC-MS/MS (data not shown). When LNCaP cells were cultured alone, the addition of 100 nM DHEA 
resulted in media concentrations of 75.3 pM T and 12.4 pM DHT in 24 h (Fig. 3B upper graphs). The 
addition of PrSC increased the concentration of T and DHT in the medium to 104.6 pM and 23.6 pM 24 h 
after addition of 100 nM DHEA, respectively (Fig. 3B upper graphs). Moreover, coculture of LNCaP cells 
with PCaSC-8 increased T and DHT to 522.6 pM and 128.9 pM 24 h after addition of DHEA, respectively 
(Fig. 3B upper graphs). The degree of increase of T and DHT by coculture corresponded with 
DHEA-induced PSA promoter activity in the presence or absence of stromal cells as observed in the 
previous experiments. 
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 To examine how DHEA was metabolized to T in this culture system, we measured the 
concentration of intermediate metabolites, androstenedione (Adione) and androstenediol (Adiol), in the 
medium (Fig. 3C lower graphs). LNCaP monoculture contained 6,456 pM Adione at 24 h from addition of 
100 nM DHEA; whereas, in the presence of stromal cells it was approximately 9,500 pM.  This finding 
indicates that there was more 3β-hydroxysteroid dehydrogenases (3β-HSDs) activity in the coculture as 
opposed to the LNCaP monoculture (Fig. 3C lower graphs). We also found that the concentration of Adiol 
in medium from the LNCaP and PrSC coculture was reduced compared with LNCaP monoculture. In 
contrast, the concentration of Adiol synthesized in the PCaSC-8 and LNCaP coculture in the presence of 
DHEA was increased to 4,374 pM at 24 h. These data indicate that DHEA is converted into T mainly via 
Adione in the presence of PrSC and via both Adione and Adiol in the presence of PCaSC-8. 
 
Expression of androgen biosynthesis enzymes 
 Several enzymes are involved in the conversion pathway of DHEA to T and DHT.  Accordingly, 
we quantified mRNA expression level of AR and androgen biosynthesis enzymes in LNCaP, PrSC and 
BDSC (Fig. 4). Real-time PCR analysis revealed that AR expression level of all stromal cells was less 
than 10 times that of the levels in LNCaP cells. Type 1 and 2 3β-hydroxysteroid dehydrogenase (HSD), 
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which catalyzes the transformation of DHEA into Adione and Adiol to T, was expressed in LNCaP cells 
and barely detectable in all stromal cells.  Stromal cells expressed types 2 and 4 17β-HSD at relatively 
high level. The level of expression of type 2 and 4 17β-HSD, which catalyzes the transformation of T into 
Adione, was different among stromal cells.  Type 3 17β-HSD, which is mainly expressed in the testes and 
catalyzes the transformation of Adione into T (27), was expressed in LNCaP cells and all stromal cells at a 
very low level. The expression level of type 5 17β-HSD (aldo-keto reductase, AKR1C3), which is 
believed to catalyze the transformation of DHEA and Adione into Adiol and T, respectively (28), is 
expressed at different levels among stromal cells although LNCaP cells show a low level of expression. 
The expression level of type 5 17β-HSD of PrSC and PCaSC-8 was not correlated with DHEA-induced 
PSA promoter activity in the presence of PrSC or PCaSC-8. 
T is converted to DHT by 5α-steroid reductase (SRD5A) in the prostate. Until now, 3 types of 
SRD5A were identified (15-19). Type 1 SRD5A was ubiquitously expressed in all cells compared with 
type 2 SRD5A. Type 3 SRD5A, which has been recently identified (19), was expressed in LNCaP cells at 
a relatively high level and well expressed in all stromal cells compared with Type 1 and 2 SRD5A. 
AKR1C2 which catalyses the transformation from DHT into the inactive form androstane-3α, 17β-diol 
(androstanediol) was expressed in all cells at a relatively low level, especially in LNCaP cells. 
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Type 5 17β-HSD does not contribute to testosterone biosynthesis in PrSC 
Dufort et al. (28) reported that Type 5 17β-HSD may be involved in DHEA metabolism in 
stromal cells. This is supported by our findings that several stromal cells, including PCaSC-8, synthesized 
large amounts of Adiol from DHEA (Fig. 3C). However, since expression levels of type 5 17β-HSD 
mRNA in stromal cells were not correlated with PSA activity as described in Fig. 2C, we focused on the 
activity (as opposed to expression level) of type 5 17β-HSD. In order to inhibit type 5 17β-HSD activity, 
we used naproxen which is a nonsteroidal anti-inflammatory drug and an AKR1C3 inhibitor (29). 
Naproxen did not inhibit PCaSC-8-induced DHEA activity in the coculture of LNCaP and PCaSC-8 cells 
(Fig. 5B). To further confirm these data, we cocultured LNCaP cells with PCaSC-8 in which type 5 
17β-HSD was knocked down using shRNA. Knockdown of type 5 17β-HSD expression in PCa-SC-8 did 
not repress DHEA-inducted PSA promoter activity (Fig. 5C). These data suggest that type 5 17β-HSD 
does not significantly contribute to the conversion of Adione into T in PCaSC. 
 
Effect of a dual 5α-reductase inhibitor on DHT biosynthesis in stromal cells 
 Since SRD5A type 1 and 3 are expressed in all stromal cells and DHT is synthesized from 
DHEA in stromal cells, we investigated if the dual 5α-reductase inhibitor, dutasteride, could block 
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DHEA-induced PSA promoter activity in the presence of stromal cells. Coculture of LNCaP cells with 
PCaSC-8 or 9 increased DHEA-induced PSA promoter activity to 10-fold or 30-fold, respectively (Fig. 
6A). Five µM dutasteride significantly inhibited PSA promoter activity induced by 100 nM DHEA as well 
as 0.1 nM T, regardless of the presence of PCaSC-8 or 9. Simultaneously, we investigated how T was 
metabolized in LNCaP monoculture by dutasteride and how DHEA were metabolized to other androgens 
by PCaSC-8 and 9 in the presence of dutasteride. When LNCaP cells were treated with T in the presence 
of 5 µM dutasteride there was minimal production of DHT and the metabolism of T was reduced in the 
medium after 24 h (Fig. 6B). Dutasteride inhibited conversion of DHEA to DHT in the LNCaP and 
PCaSC-8 or 9 coculture (Fig. 6C). Dutasteride also inhibited T biosynthesis from DHEA in LNCaP cells 
by approximately 80% at 24 h. This inhibition of T biosynthesis was also observed in coculture with 
PCaSC-8 or 9 by approximately 75% and 66%, respectively (Fig. 6C). We also measured the 
concentration of Adione and Adiol 24 h after DHEA and dutasteride treatment (Fig. 6D). The 
concentration of Adione was decreased by dutasteride in accordance with the decrease in the 
concentration of T. In contrast, the concentration of Adiol was not changed by dutasteride regardless of 
PCaSCs.  
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Comparison of androgen concentrations on coculture with those on PCaSC-8 and 9 monoculture 
The androgen concentrations measured in Fig. 6C and 6D were totals of androgens metabolized 
by LNCaP cells and PCaSC-8 or 9. Therefore, we measured the androgen concentrations in medium of 
monoculture cells treated with DHEA for 24 h (Fig. 6E and 6F). The sum of T and DHT concentrations 
from the monocultures of the LNCaP cells and the PCaSCs was less than T and DHT concentrations in 
coculture without dutasteride (compare Fig. 6E with 6C). This suggests that the presence of the two cell 
types in the coculture stimulates T and DHT synthesis in a synergistic fashion.  On the other hand, LNCaP 
cells produced much higher levels of Adione in monoculture than either PCaSC line (Fig. 6F).  The total 
Adione in the coculture is approximates that of the LNCaP  monoculture (compare Fig. 6D with 6F) 
suggesting that in coculture the total Adione may be primarily due to production by 3β-HSD in LNCaP 
cells, although this has not been definitively demonstrated. The Adiol levels in coculture with PCaSC-8 or 
9 were more than the sum of Adiol produced from DHEA by the monocultures (Compare Fig. 6D with 6F). 
This suggests that the presence of the two cell types in the coculture stimulates Adiol synthesis in a 
synergistic fashion. 
We also examined the effect of dutasteride on the androgen levels in coculture versus 
monocultures. Five µM dutasteride inhibited DHT synthesis from T in LNCaP, PCaSC-8, and PCaSC-9 
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monocultures and also Adione synthesis from DHEA in LNCaP monoculture. However, dutasteride did 
not inhibit Adione synthesis in PCaSC-8 and 9 (Fig. 6F). This result indicates that reduction of T 
concentration observed in coculture in the presence of dutasteride is due to inhibition of Adione synthesis 





The present study shows that PrSC can increase AR activity induced by the adrenal precursor 
DHEA in androgen-sensitive PCa cells and stimulate the proliferation of PCa cells. Furthermore, PCaSC 
and BDSC induce greater androgen activity than PrSC or lung-derived stromal cells. The physiological 
concentration of serum DHEA is between 3 and 15 nM although that of DHEA-sulfate (DHEA-S) ranges 
between 1 and 10 µM. This concentration of DHEA did not stimulate the proliferation during monoculture 
of LNCaP cells. We also confirmed that 10 µM DHEA-S had almost no ability to activate AR even in the 
presence of stromal cells (data not shown), thus suggesting that the LNCaP and stromal cells studied have 
little steroid sulfatase activity. 
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Our results show that physiological concentrations of DHEA stimulate the proliferation of LNCaP 
cells in the presence of stromal cells, especially cancer-derived stromal cells. The present data strongly 
suggest that biosynthesis of T and DHT in stromal cells mediates paracrine stimulation of PCa cells.  This 
activity could readily contribute to androgen deprivation-refractory PCa after ADT. Recently, Arnold et al. 
described a similar study using coculture of LAPC4 androgen-sensitive PCa cells with stromal cells (30). 
According to their study, PCa-derived stromal cells also increased PSA mRNA expression induced by 
DHEA. However, they did not identify that the proliferation of LAPC4 cells was stimulated by DHEA in 
the presence of PCa-derived stromal cells in contrast to the proliferation of LNCaP cells in our study. The 
difference between our study and their study may be due to a difference in sensitivity for androgens 
between LNCaP and LAPC4.  
Several mechanisms explaining why advanced PCa relapses during ADT have been considered 
(2,31). AR amplification, action of cytokines on the AR, induction of AR coactivators, or STAT-3 
activation (32-34) can all cause an androgen-hypersensitive state in PCa. It has also been shown that 
coculture of stromal cells with PCa-derived epithelial cells enhanced AR activity via recruitment of 
coregulators (35). Pathways which are involved in the development of treatment-resistant PCa are also 
related to the microenvironment surrounding cancer cells. In fact, PCa-stroma interactions play an 
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important key factor for prostate development and carcinogenesis (36). Increased expression of 
chemokines, cytokines, and growth factors from stromal cells drive PCa cells to a more invasive and 
malignant state (37-39). Accordingly, alterations in the stromal microenvironment as well as PCa cells 
themselves cooperate to promote malignant transformation of PCa. 
It is very likely that residual androgens in PCa tissue are involved in the progression of PCa that 
has become androgen-hypersensitive. Our data indicate that the adrenal androgen precursor DHEA acts as 
precursor for synthesis of residual androgens in PCa tissues.  Recently, many physicians have adopted 
combined androgen blockade using an LH-RH agonist and an antiandrogen as initial treatment for 
advanced PCa. However, metastatic PCa relapses and serum PSA values increase a few years later. 
Ketoconazole, which inhibits the synthesis of adrenal DHEA, is often use for HRPC in West European 
countries, and have a response rate of about 60% but the response is of short duration. Furthermore, in 
phase II studies using the CYP17A inhibitor abiraterone, which blocks DHEA synthesis, PSA declines of 
>50% in 12/21 (57%) patients have been observed (40) although cessation of the antiandrogen, by itself, 
could have caused a significant effect on PSA. These results suggest that adrenal DHEA contributes to 
>50% of relapses of advanced metastatic PCa. 
Even after ADT, DHT remains in the prostate cancer tissue at 20–40% of untreated prostate tissue 
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although serum DHT levels decrease to <10% after ADT (7, 8, 11, 41). Mohler et al. demonstrated that 
recurrent PCa tissue retains T at around 50% of benign prostatic tissue (42). Recently, Montgomery has 
demonstrated that T levels within metastases from anorchid men were significantly higher than levels 
within primary PCa from untreated eugonadal men (43). These reports indicate that T and DHT 
accumulate in PCa tissue and metastatic lesions after ADT. These data as well as the presence of 
steroidogenic enzymes in PCa tissue strongly suggest that T is synthesized from adrenal DHEA not only 
in the testes but also in PCa tissue and metastatic lesions, by ‘intracrine synthesis’ (8, 15). 
The mechanisms through which T and DHT are synthesized in PCa tissue and how they contribute 
to PCa progression are unclear.  Our data indicate that stromal cells promote androgen production in PCa 
either directly or through simulation of PCa epithelial cell-mediated production of androgens.  The PSA 
promoter activity induced by DHEA was only moderate in LNCaP monocultures. However, coculture 
with stromal cells, especially, PCaSCs, strongly activated PSA promoter activity induced by DHEA. 
Although our results are consistent with Arnold et al’s observation that T synthesized from DHEA in 
PCa-derived stromal cells contributed to PSA induction in LAPC4 (30), we extended these studies further 
to elucidate which pathways were involved in T synthesis. Specifically, we identified that the increased 
level of DHEA-induced AR activity by stromal cells was dependent on the synthesized level of T and 
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DHT achieved by coculture. (Fig. 3 and Fig. 6). Furthermore, the ability the predominant pathways (via 
Adiol and/or via Adione) of T biosynthesis from DHEA were dependent on stromal cells. These results 
suggest that enzymatic activities which catalyze conversion of DHEA to T or DHT via Adiol or Adione 
differ among stromal cells and coordinately with cancer cells. 
When we examined the expression of androgen biosynthesis enzymes, expression pattern was 
different among each of stromal cells.  Furthermore, the expression pattern of type 5 17β-HSD in stromal 
cells, whose expression has been reported to be increased in PCa (21), did not correlate with increase of 
DHEA-induced PSA promoter activity by stromal cells. This discrepancy may be due to several reasons: 
1) expression level of androgen biosynthesis enzymes mRNA does not always reflect its enzymatic 
activity; 2) total activity of all 17β-HSDs may be important for the global conversion of DHEA to Adiol or 
Adione to T; and 3) recently, type 15 17β-HSD has been proposed to convert Adione to T and thus may 
impact the overall response (18).  
DHT is usually synthesized from T by SRD5A1 and 2 in the prostate. Although SRD5A2 is 
predominantly expressed in the normal prostate, recent evidence shows that SRD5A1 is highly expressed 
in PCa and HRPC; whereas, SRD5A2 is not highly expressed (44). Consistent with this finding, we also 
observed that SRD5A1 was highly expressed in LNCaP cells and all stromal cells. Uemura et al. 
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discovered SRD5A3 in HRPC (19). SRD5A3 is predominantly expressed in HRPC but not in 
androgen-sensitive PCa. We observed that both LNCaP cells and PCaSC from PCa patients expressed 
SRD5A3 mRNA and that dutasteride almost completely blocked PSA promoter activity induced by T and 
DHEA in the presence or absence of stromal cells. Dutasteride may inhibit SRD5A3 activity as well as 
SRD5A1 and SRD5A2 activity. Interestingly, when LNCaP cells were treated with DHEA regardless of 
the presence or absence of stromal cells, dutasteride inhibited not only DHT biosynthesis but also T and 
Adione biosynthesis from DHEA in LNCaP cells. However, inhibition of Adione biosynthesis from 
DHEA by dutasteride was not observed in PCaSC-8 and 9 (Fig. 6F). It is not clear why dutasteride 
inhibited Adione synthesis only in LNCaP cells.  Recently, Lazier et al. demonstrated that dutasteride not 
only inhibits the conversion from T to DHT but also acted as an antiandrogen (45). We also confirmed that 
dutasteride inhibited PSA promoter activity induced by DHT in LNCaP cells (data not shown). Taken 
together, dutasteride may have a variety of inhibitory functions on androgen biosynthesis and AR action.  
 On the basis of our data and previous reports, we propose an interactive model for the interaction 
between PCa cells and the surrounding stromal cells (Fig. 7). The proliferation of PCa is highly dependent 
upon T and DHT secreted from the testes, the T of testicular origin adds to the T made locally from DHEA 
(15). Although ADT induces apoptosis of many PCa epithelial cells, stromal cells surrounding PCa cells 
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can still survive. Then oncogenes, cytokines, and growth factors may affect survival and progression, 
especially when only partial androgen blockade or monotherapy is used. On the other hand, PCaSC can 
synthesize T and DHT from DHEA coordinately with cancer cells, and secrete them to the surrounding 
area in a paracrine fashion. Surviving PCa cells receive an androgenic supply from stromal cells, and 
progression of the cancer continues. However, we cannot eliminate that some growth factors or cytokines 
induced by DHEA in either stromal or epithelial cells affect LNCaP proliferation independent of AR. 
In conclusion, we have demonstrated that the concentration of T and DHT in PCa tissue is 
higher than in serum after ADT.  This results from biosynthesis of T from DHEA in PCa-derived tissues. It 
is possible that both stromal and epithelial cells may contribute to the conversion of DHEA to T. Our 
coculture assay system is extremely useful for measuring total DHEA activity which results in AR 
activation in PCa and stromal cells. Such data could support the development of new drugs to inhibit 
biosynthesis of androgens. Moreover, using this assay system, there may be a possibility of predicting 
relapse and the time of relapse at diagnosis of advanced PCa, depending upon the level of steroidogenic 
enzyme expression. In the present study, we used stromal cells from high-grade PCa tissue (Gleason 7, 8, 
and 9).  It would be interesting if we could culture stromal cells from low grade PCa tissue and perform the 
same study; however, these were not readily available for our studies. Additional studies are needed to 
Page 29 of 54
erc@endocrinology.org
Manuscript submitted for review to Endocrine-Related Cancer
For Review Only
 30 
assess which enzymes are the most involved in the biosynthesis of androgens in PCa tissue. The present 
data also indicate that monotherapy of PCa with medical or surgical castration alone or an antiandrogen 
alone is an insufficient treatment for PCa at any stage of the disease, due to the major importance of the 
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Fig. 1 Effect of PrSC on PSA promoter activity and proliferation of LNCaP cells in the presence of DHEA. 
(A) After 5 x 104 LNCaP cells were transfected with 0.4 µg pGLPSAp-5.8 for 12 h, the cells were 
cocultured in DMEM-5% CCS with 0, 2 x104, or 4 x 104 PrSC cells for 12 h. Consequently, both cells 
were treated with DHEA for 24 h and cells were lysed. As a positive control, transfected LNCaP cells 
were treated with 0.1 nM DHT for 24 h without PrSC (column of oblique lines). The absolute luciferase 
activities were measured. (B) LNCaP cell proliferation in the absence or presence of PrSC. Twenty-four h 
after 3 x 104 LNCaP cells were cultured on the lower chamber, PrSC cells were seeded on the upper 
chamber. Twelve h later, cells were treated with increasing concentrations of DHEA for 4 days and 
counted. As a positive control, LNCaP cells were treated with 0.1 nM DHT for 4 days for 24 h without 
PrSC (column of oblique lines).  (C) LNCaP cells transfected with pGL3PSAp-5.8 were cocultured with 
or without PrSC for 12 h. Those cells were treated with 100 nM DHEA in the absence or presence of 1 µM 
bicalutamide for 24 h, and then luciferase activities were measured. Transfected LNCaP cells were also 
treated with 0.1 nM DHT with or without bicalutamide for 24 h as a positive control. (D) AR knockdown 
of AR in LNCaP cells.  After AR of LNCaP cells were knocked-down using AR siRNA-1, or AR siRNA-2, 
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cells were transfected with pGL3PSAp-5.8 for 12 h. Transfected LNCaP cells were cocultured with or 
without PrSC. Consequently, cells were treated with or without 100 nM DHEA (+) for 24 h. As a positive 
control, cells were treated with 0.1 nM DHT for 24 h. (E) LNCaP cells transfected with pGL3PSAp-5.8 
were cocultured with PrSC transfected with 50 nM NT siRNA or AR siRNA-1 for 48 h. The aliquot of 
transfected PrSC were used for RT-PCR analysis of AR knockdown. Those cells were treated with 100 
nM DHEA for 24 h, and then luciferase activity was measured. These coculture experiments were 
performed at least twice with reproducible data. The data are presented as the mean ± SD of triplicate 
measurements. 
 
Fig. 2 Effect of stromal cells from different tissues and PCa tissues on DHEA and DHT-induced PSA 
promoter activity and proliferation. (A) Effect of stromal cells from different tissues on DHEA and 
DHT-induced PSA promoter activity. Stromal cells from different tissues, PrSC, HMSC, and HLFa., were 
cocultured with LNCaP cells transfected with pGL3PSAp-5.8 and treated with 100 nM DHEA for 24 h 
and luciferase activities were measured. (B) Confirmation of stromal cells from different PCa patients and 
the normal rib bone. Expression of vimentin and KGF was observed in prostate-derived stromal cells by 
RT-PCR. Expression of cbfa1 and osteopontin (OPN) was also observed in BDSC-1 and BDSC-2 by 
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RT-PCR. (C) Effect of stromal cells from different PCa patients and the normal rib bone on PSA promoter 
activity. Columns indicate the relative acceleration ratio compared with 100 nM DHEA alone in the 
absence of stromal cells, and the number above each column represents relative induction ratio compared 
with PrSC. (D) Effect of different PCaSCs on LNCaP cell proliferation. Twenty-four h after 3 x 104 
LNCaP cells were cultured on the lower chamber, PCaSC-5, 8, or 9 cells were seeded on the upper 
chamber. Twelve h later, cells were treated with increasing concentrations of DHEA for 4 days and 
counted. Medium was changed every 2 days and DHEA was added to medium. These coculture 
experiments were performed at least twice with reproducible data. The data are presented as the mean ± 
SD of triplicate measurements. 
 
Fig. 3 Androgen biosynthesis from DHEA in PrSC and PCaSC-8. (A) LNCaP cells transfected with 
pGL3PSAp-5.8 were cocultured with PrSC or PCaSC-8, treated with 100 nM DHEA for 24 h, and 
measured luciferase activity as described in Fig. 1. As a positive control, transfected LNCaP cells were 
treated with 0.1 nM DHT for 24 h (red column). This coculture experiments were performed at least twice 
with reproducible data. (B) Concentration of T, DHT, Adione, and Adiol in the medium used for coculture 
with LNCaP and stromal cells after treating with 100 nM DHEA. Twelve h after starting culture of 5 x 104 
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LNCaP cells with or without 5 x 104  PrSC or PCaSC-8 cells, 100 nM DHEA was added to the medium. 
Then aliquots of medium were collected after 12 h and 24 h for measuring concentration of T, DHT, 
Adione, and Adiol by LC-ESI-MS/MS. A red line shows concentration of DHT in the medium used for 
monoculture of LNCaP cells after treating with 0.1 nM DHT as described in Fig. 3A. The lower limit of 
quantitation of T, DHT, DHEA, Adione, and Adiol were 5, 2.5, 5, 2.5, and 1 pg/assay, respectively. The 
data are presented as the mean ± SD of triplicate measurements. 
 
Fig. 4 Real-time RT-PCR analysis of AR and androgen biosynthesis enzymes mRNA in LNCaP cells and 
stromal cells. Expression of AR, various HSD17s, HSD3B-1 and 2, SRD5As, and AKR1C2 mRNA in 
various stromal cells was confirmed using real-time RT-PCR analysis. 1. LNCaP cells treated without 
androgen for 24 h in DMEM-5% CCS; 2. LNCaP cell treated with 10 nM DHT for 24 h; 3. PC-3 cells; 4. 
DU145 cells; 5. PrSC; 6.PCaSC-1; 7. PCaSC-2; 8. PCaSC-5; 9. PCaSC-6; 10. PCaSC-7; 11. PCaSC-8; 12. 
PCaSC-9; 13. BDSC-1; 14. BDSC-2. 
 
Fig. 5 Effect of type 5 17β-HSD on DHEA-induced PSA promoter activity.  (A) Effect of HSD17B-5 
inhibitor, naproxen and HSD17B-5 shRNA on DHEA-induced PSA promoter activity. After 5 x 104 
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LNCaP cells were transfected with 0.4 µg pGLPSAp-5.8 for 12 h, the cells were cocultured with 0 or 5 x 
104 PCaSC-8 cells for 12 h. Consequently both cells were treated with 100 nM DHEA in the absence or 
presence of 5 µM naproxen for 24 h, and then the absolute luciferase activities were measured. (B) 
knockdown of HSD17B-5 mRNA and PSA promoter activity. After PCaSC-8 was transfected with 50 nM 
HSD17B-5 siRNA for 48 h, RNA was purified and subjected to RT-PCR of HSD17B-5 mRNA. As a 
negative control, 100 nM non-targeting (NT) siRNA was also transfected. LNCaP cells transfected with 
pGLPSAp-5.8 were cocultured with siRNA-transfected PCaSC-8. Then LNCaP and PCaSC-8 cells were 
treated with 100 nM DHEA for 24 h and luciferase activities were measured. These coculture experiments 
were performed at least twice with reproducible data. The data are presented as the mean ± SD of triplicate 
measurements. NS means not statistically significant difference. 
 
Fig. 6 Effect of 5α-reductase inhibitor, dutasteride, on T or DHEA-induced PSA promoter activity and 
concentration of various androgens in the medium. (A) After 5 x 104 LNCaP cells were transfected with 
0.4 µg pGLPSAp-5.8 for 12 h, the cells were cocultured with 5 x 104 PCaSC-8 or PCaSC-9 cells or 
without stromal cells for 12 h. Consequently both cells were treated with 100 nM DHEA with or without 5 
µM dutasteride (Dut) for 24 h, and luciferase assay was performed. As a positive control, transfected 
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LNCaP cells were treated with 0.1 nM T for 24 h. These coculture experiments were performed at least 
twice with reproducible data. The data are presented as the mean ± SD of triplicate measurements. (B) 
Concentration of T, DHT, Adione, and Adiol in the medium treated with 0.1 nM T with or without Dut. 
Twenty-four h after treating cocultured LNCaP cells in the presence of 0.1 nM T with or without Dut the 
medium was collected for LC-ESI-MS/MS as described in Fig. 3. (C) and (D) Concentration of T and 
DHT (C), Adione and Adiol (D) in the medium treated with 100 nM DHEA with or without dutasteride. 
Twenty-four h after treating cocultured LNCaP cells with PCaSC-8 or 9 in the presence of 100 nM DHEA 
with or without Dut, the medium was collected for LC-ESI-MS/MS. (E) and (F) Concentration of T and 
DHT (E) and Adione and Adiol (F) in the medium of LNCaP, PCaSC-8, and PCaSC-9 monoculture 
treated with DHEA with or without dutasteride. Twenty-four h after treating LNCaP cells, PCaSC-8, and 
PCaSC-9 in the presence of 100 nM DHEA with or without dutasteride, the medium was collected for 
LC-ESI-MS/MS.  The data are presented as the mean ± SD of triplicate measurements. 
 
 
Fig. 7 Mechanism of how DHEA contributes to androgen therapy non-responsive PCa.  Prior to androgen 
deprivation therapy (ADT), T from the testes plays a major role in the androgen activity in the prostate; 
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whereas, the adrenal androgen DHEA plays a minor role. After ADT, in addition to the growth factors and 
cytokines from PCa-derived stromal cells that stimulate the proliferation of PCa, residual PCa cells 
become androgen-hypersensitive through various mechanisms and simultaneously PCa-derived stromal 
cells synthesize T, DHT, and precursors from DHEA coordinately. These synthesized androgens induce 
AR activity and stimulate the progression of PCa in a paracrine fashion. 
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Stromal cells 
PSA (ng/ml) on 
diagnosis Gleason score Stage on diagnosis 
PCaSC-1 4799 5+5 T3a, N0, M1 
PCaSC-2 263 4+4 T3b, N0, M0 
PCaSC-5 76.9 4+3 T3a, N0, M1 
PCaSC-6 46.4 4+4 T3a, N1, M0 
PCaSC-7 648 4+3 T4, N1, M1 
PCaSC-8 246 4+5 T4, N0, M1 
PCaSC-9 180 5+4 T3b, N0, M0 
    
Table 1 Characteristics of PCa patients on diagnosis 
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  Forward (5'-3') Reverse (5'-3') Condtion 
GAPDH GACCACAGTCCATGCCATCA TCCACCACCCTGTTGCTGTA 94C for 15 sec, 56C for 30 sec, 72C for 30 sec 
hAR TCCAAATCACCCCCCAGGAA GACATCTGAAAGGGGGCATG 94C for 15 sec, 56C for 30 sec, 72C for 30 sec 
HSD17B-1 ACAATCATCTCCCACCTCCCAACGC CATGGTGAGACTGTGGGGAGAGGCT 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
HSD17B-2 AACAATGCTGGGGTGCTTGGCTTTC GGCGTGTAATAGGCAAAAGGGCTCT 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
HSD17B-3 CCTGTTTCCTTGGCCTCTCTACTCC GGGACTGGTGAGGAAAAGGTTGTGC 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
HSD17B-4 GGCTGCTTTGTACCGCCTCAGTGGA GTAGTGTGCCCTTCAGAGCTTGGCG 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
HSD17B-5 GAGAAGTAAAGCTTTGGAGGTCACA TAGCAATTTACTCCGGTTGAAATAC 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
HSD17B-6 AGATGGAGAGCATCGCTGCAGCTAC TGCACCGATGTCAGAGCATGTTCCA 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
HSD17B-7 AAGGCAAGGAACCCTACAGCTCTTC CTCAAGAGATCCTCCCACCTCATCC 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
HSD17B-8 CTGCTTTTCTCGCCCACCATCTGTC TGCGACCACATCTGCCACATCCTCA 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
HSD17B-10 TGTGGCTGCCTTCGAGGGTCAGGTT TGGGCTTCCTCCCAAGCTGGAGAGT 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
HSD17B-11 CATGTCTCGGTCCCCTTCTTACTGG GGAAACGCTCAGGAAGGATCCTTTC 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
HSD3B-1&2 AGCAAAAAGCTTGCTGAGAAGGCTG TTCTGCTTGGCTTCCTCCCAGCTGT 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
SRD5A1 TGGAGAAATCATGGAGTGGTGTGGC TCCTCCTCTATCCCCAAGTTCTCCA 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
SRD5A2 ATACCCTGATGGGTGGTACACAGAC GCTTCAGTTGGGGATCAGGATAGGG 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
SRD5A3 GCAGGAGTGGTCATTCACTGTAACC CTGTACTTTGGGCTCCAGACTTCAC 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
AKR1C2 TAAAAGTAAAGCTCTAGAGGCCGTC CAGCAGTTTTCTCTGGTTGAAGTAA 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
vimentin TGCAGGCTCAGATTCAGGAACAGCA AGGTGACGAGCCATTTCCTCCTTCA 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
KGF GGAAATCAGGACAGTGGCAGTTGGA CAAATCCTGCCAGAAGCCTGTAGGT 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
cbfa1 CCCACGAATGCACTATCCAGCCACC ATTCGAGGTGGTGGTGCATGGCGG A 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
OPN TATGATGGCCGAGGTGATAGTGTGG TAATCTGGACTGCTTGTGGCTGTGG 94C for 15 sec, 65C for 30 sec, 72C for 30 sec 
  
  
Table 2 Sequence of primers and reaction condition of PCR 
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Fig. 1 Effect of PrSC on PSA promoter activity and proliferation of LNCaP cells in the presence of 
DHEA. (A) After 5 x 104 LNCaP cells were transfected with 0.4 µg pGLPSAp-5.8 for 12 h, the cells 
were cocultured in DMEM-5% CCS with 0, 2 x104, or 4 x 104 PrSC cells for 12 h. Consequently, both 
cells were treated with DHEA for 24 h and cells were lysed. As a positive control, transfected LNCaP 
cells were treated with 0.1 nM DHT for 24 h without PrSC (column of oblique lines). The absolute 
luciferase activities were measured. (B) LNCaP cell proliferation in the absence or presence of PrSC. 
Twenty-four h after 3 x 104 LNCaP cells were cultured on the lower chamber, PrSC cells were 
seeded on the upper chamber. Twelve h later, cells were treated with increasing concentrations of 
DHEA for 4 days and counted. As a positive control, LNCaP cells were treated with 0.1 nM DHT for 4 
days for 24 h without PrSC (column of oblique lines).  (C) LNCaP cells transfected with pGL3PSAp-
5.8 were cocultured with or without PrSC for 12 h. Those cells were treated with 100 nM DHEA in 
the absence or presence of 1 µM bicalutamide for 24 h, and then luciferase activities were 
measured. Transfected LNCaP cells were also treated with 0.1 nM DHT with or without bicalutamide 
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for 24 h as a positive control. (D) AR knockdown of AR in LNCaP cells.  After AR of LNCaP cells were 
knocked-down using AR siRNA-1, or AR siRNA-2, cells were transfected with pGL3PSAp-5.8 for 12 h. 
Transfected LNCaP cells were cocultured with or without PrSC. Consequently, cells were treated with 
or without 100 nM DHEA (+) for 24 h. As a positive control, cells were treated with 0.1 nM DHT for 
24 h. (E) LNCaP cells transfected with pGL3PSAp-5.8 were cocultured with PrSC transfected with 50 
nM NT siRNA or AR siRNA-1 for 48 h. The aliquot of transfected PrSC were used for RT-PCR analysis 
of AR knockdown. Those cells were treated with 100 nM DHEA for 24 h, and then luciferase activity 
was measured. These coculture experiments were performed at least twice with reproducible data. 
The data are presented as the mean ± SD of triplicate measurements.  
199x266mm (300 x 300 DPI)  
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Fig. 2 Effect of stromal cells from different tissues and PCa tissues on DHEA and DHT-induced PSA 
promoter activity and proliferation. (A) Effect of stromal cells from different tissues on DHEA and 
DHT-induced PSA promoter activity. Stromal cells from different tissues, PrSC, HMSC, and HLFa., 
were cocultured with LNCaP cells transfected with pGL3PSAp-5.8 and treated with 100 nM DHEA for 
24 h and luciferase activities were measured. (B) Confirmation of stromal cells from different PCa 
patients and the normal rib bone. Expression of vimentin and KGF was observed in prostate-derived 
stromal cells by RT-PCR. Expression of cbfa1 and osteopontin (OPN) was also observed in BDSC-1 
and BDSC-2 by RT-PCR. (C) Effect of stromal cells from different PCa patients and the normal rib 
bone on PSA promoter activity. Columns indicate the relative acceleration ratio compared with 100 
nM DHEA alone in the absence of stromal cells, and the number above each column represents 
relative induction ratio compared with PrSC. (D) Effect of different PCaSCs on LNCaP cell 
proliferation. Twenty-four h after 3 x 104 LNCaP cells were cultured on the lower chamber, PCaSC-5, 
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8, or 9 cells were seeded on the upper chamber. Twelve h later, cells were treated with increasing 
concentrations of DHEA for 4 days and counted. Medium was changed every 2 days and DHEA was 
added to medium. These coculture experiments were performed at least twice with reproducible 
data. The data are presented as the mean ± SD of triplicate measurements.  
199x266mm (300 x 300 DPI)  
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Fig. 3 Androgen biosynthesis from DHEA in PrSC and PCaSC-8. (A) LNCaP cells transfected with 
pGL3PSAp-5.8 were cocultured with PrSC or PCaSC-8, treated with 100 nM DHEA for 24 h, and 
measured luciferase activity as described in Fig. 1. As a positive control, transfected LNCaP cells 
were treated with 0.1 nM DHT for 24 h (red column). This coculture experiments were performed at 
least twice with reproducible data. (B) Concentration of T, DHT, Adione, and Adiol in the medium 
used for coculture with LNCaP and stromal cells after treating with 100 nM DHEA. Twelve h after 
starting culture of 5 x 104 LNCaP cells with or without 5 x 104  PrSC or PCaSC-8 cells, 100 nM DHEA 
was added to the medium. Then aliquots of medium were collected after 12 h and 24 h for 
measuring concentration of T, DHT, Adione, and Adiol by LC-ESI-MS/MS. A red line shows 
concentration of DHT in the medium used for monoculture of LNCaP cells after treating with 0.1 nM 
DHT as described in Fig. 3A. The lower limit of quantitation of T, DHT, DHEA, Adione, and Adiol were 
5, 2.5, 5, 2.5, and 1 pg/assay, respectively. The data are presented as the mean ± SD of triplicate 
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measurements.  
199x266mm (300 x 300 DPI)  
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Fig. 4 Real-time RT-PCR analysis of AR and androgen biosynthesis enzymes mRNA in LNCaP cells 
and stromal cells. Expression of AR, various HSD17s, HSD3B-1 and 2, SRD5As, and AKR1C2 mRNA 
in various stromal cells was confirmed using real-time RT-PCR analysis. 1. LNCaP cells treated 
without androgen for 24 h in DMEM-5% CCS; 2. LNCaP cell treated with 10 nM DHT for 24 h; 3. PC-
3 cells; 4. DU145 cells; 5. PrSC; 6.PCaSC-1; 7. PCaSC-2; 8. PCaSC-5; 9. PCaSC-6; 10. PCaSC-7; 
11. PCaSC-8; 12. PCaSC-9; 13. BDSC-1; 14. BDSC-2.  
199x266mm (300 x 300 DPI)  
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Fig. 5 Effect of type 5 17β-HSD on DHEA-induced PSA promoter activity.  (A) Effect of HSD17B-5 
inhibitor, naproxen and HSD17B-5 shRNA on DHEA-induced PSA promoter activity. After 5 x 104 
LNCaP cells were transfected with 0.4 µg pGLPSAp-5.8 for 12 h, the cells were cocultured with 0 or 
5 x 104 PCaSC-8 cells for 12 h. Consequently both cells were treated with 100 nM DHEA in the 
absence or presence of 5 µM naproxen for 24 h, and then the absolute luciferase activities were 
measured. (B) knockdown of HSD17B-5 mRNA and PSA promoter activity. After PCaSC-8 was 
transfected with 50 nM HSD17B-5 siRNA for 48 h, RNA was purified and subjected to RT-PCR of 
HSD17B-5 mRNA. As a negative control, 100 nM non-targeting (NT) siRNA was also transfected. 
LNCaP cells transfected with pGLPSAp-5.8 were cocultured with siRNA-transfected PCaSC-8. Then 
LNCaP and PCaSC-8 cells were treated with 100 nM DHEA for 24 h and luciferase activities were 
measured. These coculture experiments were performed at least twice with reproducible data. The 
data are presented as the mean ± SD of triplicate measurements. NS means not statistically 
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significant difference.  
199x266mm (300 x 300 DPI)  
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Fig. 6 Effect of 5α-reductase inhibitor, dutasteride, on T or DHEA-induced PSA promoter activity and 
concentration of various androgens in the medium. (A) After 5 x 104 LNCaP cells were transfected 
with 0.4 µg pGLPSAp-5.8 for 12 h, the cells were cocultured with 5 x 104 PCaSC-8 or PCaSC-9 cells 
or without stromal cells for 12 h. Consequently both cells were treated with 100 nM DHEA with or 
without 5 µM dutasteride (Dut) for 24 h, and luciferase assay was performed. As a positive control, 
transfected LNCaP cells were treated with 0.1 nM T for 24 h. These coculture experiments were 
performed at least twice with reproducible data. The data are presented as the mean ± SD of 
triplicate measurements. (B) Concentration of T, DHT, Adione, and Adiol in the medium treated with 
0.1 nM T with or without Dut. Twenty-four h after treating cocultured LNCaP cells in the presence of 
0.1 nM T with or without Dut the medium was collected for LC-ESI-MS/MS as described in Fig. 3. 
(C) and (D) Concentration of T and DHT (C), Adione and Adiol (D) in the medium treated with 100 
nM DHEA with or without dutasteride. Twenty-four h after treating cocultured LNCaP cells with 
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PCaSC-8 or 9 in the presence of 100 nM DHEA with or without Dut, the medium was collected for 
LC-ESI-MS/MS. (E) and (F) Concentration of T and DHT (E) and Adione and Adiol (F) in the medium 
of LNCaP, PCaSC-8, and PCaSC-9 monoculture treated with DHEA with or without dutasteride. 
Twenty-four h after treating LNCaP cells, PCaSC-8, and PCaSC-9 in the presence of 100 nM DHEA 
with or without dutasteride, the medium was collected for LC-ESI-MS/MS.  The data are presented 
as the mean ± SD of triplicate measurements.  
199x266mm (300 x 300 DPI)  
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Fig. 7 Mechanism of how DHEA contributes to androgen therapy non-responsive PCa.  Prior to 
androgen deprivation therapy (ADT), T from the testes plays a major role in the androgen activity in 
the prostate; whereas, the adrenal androgen DHEA plays a minor role. After ADT, in addition to the 
growth factors and cytokines from PCa-derived stromal cells that stimulate the proliferation of PCa, 
residual PCa cells become androgen-hypersensitive through various mechanisms and simultaneously 
PCa-derived stromal cells synthesize T, DHT, and precursors from DHEA coordinately. These 
synthesized androgens induce AR activity and stimulate the progression of PCa in a paracrine 
fashion.  
199x266mm (300 x 300 DPI)  
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